Review

The IGF/IGFBP system in CNS malignancy

W Zumkeller¹ and M Westphal²

¹ Martin-Luther- University Halle-Wittenberg, University Hospital, Department of Pediatrics, Ernst-Grube-Str. 40, 06097 Halle/Saale, Germany
² University Hospital Eppendorf, Department of Neurosurgery, Martinistr. 52, 20246 Hamburg, Germany

Correspondence to:
Dr Zumkeller walter.zumkeller{at}medizin.uni-halle.de

The insulin-like growth factor (IGF) system includes IGF-I and IGF-II, the type I and type II IGF receptors, and specific IGF binding proteins (IGFBP-1 to IGFBP-6). These factors regulate both normal and malignant brain growth. Enhanced expression of IGF-I and IGF-II mRNA transcripts has been demonstrated in gliomas, meniningiomas, and other tumours. Abnormal imprinting of IGF-II occurs in gliomas, medulloblastomas, and meningiomas. Both types of IGF receptor are expressed in gliomas and, in particular, the type I IGF receptor appears to be upregulated in malignant brain tissue. Antisense IGF-I receptor mRNA induces an antitumour response, resulting in complete brain tumour regression. Clinical trials for the treatment of brain tumours in humans based on a gene transfer protocol using IGF-I receptor antisense are under way. All six IGFBPs are expressed to a variable extent in brain tumours. High concentrations of IGFBP-2 are found in cerebrospinal fluid from patients with malignant central nervous system tumours; therefore, IGFBP-2 might be a useful marker for these tumours. IGFBP-4 appears to be a negative regulator of tumour proliferation. Both in vitro and in vivo experiments suggest that the IGF system represents an important target for the treatment of malignant central nervous system tumours and the ongoing trials should provide valuable information for future therapeutic approaches.

Key Words: insulin-like growth factor • insulin-like growth factor binding protein • central nervous system • brain tumours

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• de Bont, J. M., Packer, R. J., Michiels, E. M., Boer, M. L. d., Pieters, R. (2008). Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective. Neuro Oncol 10: 1040-1060 [Abstract] [Full Text]  
• Lonn, S., Inskip, P. D., Pollak, M. N., Weinstein, S. J., Virtamo, J., Albanes, D. (2007). Glioma Risk in Relation to Serum Levels of Insulin-Like Growth Factors. Cancer Epidemiol. Biomarkers Prev. 16: 844-846 [Abstract] [Full Text]  
• Sim, F. J., Keyoung, H. M., Goldman, J. E., Kim, D. K., Jung, H.-W., Roy, N. S., Goldman, S. A. (2006). Neurocytoma Is a Tumor of Adult Neuronal Progenitor Cells. J. Neurosci. 26: 12544-12555 [Abstract] [Full Text]  
• Russo, V. C., Gluckman, P. D., Feldman, E. L., Werther, G. A. (2005). The Insulin-Like Growth Factor System and Its Pleiotropic Functions in Brain. Endocr. Rev. 26: 916-943 [Abstract] [Full Text]  
• Brar, B. K., Jonassen, A. K., Egorina, E. M., Chen, A., Negro, A., Perrin, M. H., Mjos, O. D., Latchman, D. S., Lee, K.-F., Vale, W. (2004). Urocortin-II and Urocortin-III Are Cardioprotective against Ischemia Reperfusion Injury: An Essential Endogenous Cardioprotective Role for Corticotropin Releasing Factor Receptor Type 2 in the Murine Heart. Endocrinology 145: 24-35 [Abstract] [Full Text]  
• Solomon, A., Grueterich, M., Li, D.-Q., Meller, D., Lee, S.-B., Tseng, S. C. G. (2003). Overexpression of Insulin-like Growth Factor-Binding Protein-2 in Pterygium Body Fibroblasts. IOVS 44: 573-580 [Abstract] [Full Text]